The Senté Team
An Onassis Foundation Scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and his M.Sc. degree in Microbiology and Ph.D. degree in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is Chairman of the Board of Directors for Apricus Biosciences Inc., and a member of the Board of Directors of the Biotechnology Industry Organization (BIO), and Zosano Pharma Inc., and is a co-founder and a member of the Board of Directors of Senté , Inc. Additionally, Dr. Xanthopoulos received the Ernst & Young Entrepreneur of the Year Award in Health Sciences in 2006 and was named Most Admired CEO by the San Diego Business Journal in 2013.
Marios Fotiadis – Founder / Board Member, has CEO and venture capital experience in life sciences with SG Capital Partners and Advent International. He currently serves as President & CEO of the Vandell Group.
Faheem Hasnain – Chairman of the Board, has over 20 years experience in the pharmaceuticals industry with extensive commercialization experience in senior management roles. He is currently President and Chief Executive Officer of Receptos, Inc. and the previous President and CEO of Facet Biotech, which sold to Abbot Laboratories for over $700M in March of 2010. He has launched more than 20 new products in more than 30 indications with line extensions across 12 therapeutic areas. He has previously served in executive roles with Biogen Idec; Oncology Therapeutics Network (OTN), a specialty pharmacy distributor and subsidiary to Bristol-Myers Squibb Company; and GlaxoSmithKline where he held numerous roles including Commercial and Vice President, Dermatology business.
Neil Sandler – Board Member, is Co-founder of Symphony Capital, a $300 million life sciences private equity firm. He has also served as a Healthcare Partner at Behrman Capital, a $1.8 billion private equity firm. Neil has done over 125 financings and mergers and acquisitions exceeding $13 billion in value as an investment banker, primarily at PaineWebber and Robertson Stephens. He has served on the board of directors of five biopharmaceutical partnerships with Centocor, Genzyme, Synergen (Amgen), Isis Pharmaceuticals and Alexza Pharmaceuticals.
Magda Marquet, Ph.D. – Board Member, Dr. Marquet is the founder and co-Chair of Ajinomoto Althea Technologies, and served as its co-President and CEO for ten years. Dr. Marquet is also founder and co-Chair of Althea Dx, a spin-off of Althea Technologies focusing in companion diagnostics development. She is the Chairwoman of BIOCOM and she is on the Board of UCSD Moores Cancer Center. She is currently involved as investor, adviser, and board member in over twenty local San Diego companies. Dr. Marquet has over twenty-five years of experience in the biotechnology industry in the United States and Europe. She was formerly Executive Director of Pharmaceutical Development at Vical Incorporated, where she patented several novel methods for the production of clinical grade DNA for use in gene therapy and DNA vaccines. Prior to joining Vical, Dr. Marquet held management positions at Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. Dr. Marquet holds a Ph.D. in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet was the winner of the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category.
Michael York – President & Chief Executive Officer, Mr. York brings to Sente more than 20 years of management, commercial and finance experience in the biopharmaceutical industry, including leadership positions in sales, marketing, pricing, managed care, commercial operations, and investor relations at early stage and global life sciences companies.
Most recently, Michael was Vice President, Sales and Marketing for the Specialty and Rare Disease Business Unit at Amylin Pharmaceuticals where he was responsible for leading worldwide development and commercialization of Amylin products and pipeline assets in the endocrine specialty market. Prior to this role, Michael served as Senior Director of Investor Relations at Amylin and held responsibility for managing the financial global brand. Michael has significant experience in developing relationships with U.S. and European equity analysts and investment bankers along with attracting and retaining long-term investors, including mutual funds and hedge funds. Michael holds a BA degree in Public Administration and Economics from San Diego State University and a MBA degree from the University of Redlands.
Joe C. Vasconcellos – Chief Financial Officer, has over 28 years of financial experience and serves as a consultant and part time CFO for over a dozen small to medium size businesses. He holds a Certificate in Financial Planning from the ICFP.
Aaron Hasnain – Manager of Account Relations & Director of New Media, has extensive experience working with life science companies, and is supported with a strong background in public relations, communication and social media. Aaron has helped multiple companies in the industry reach their target audiences, and specializes in the delivery of messages through new media. He has previously served in numerous public relations roles with companies on both the East and West coasts. Aaron holds a BA degree in Communication from the University of California Santa Barbara.
Mark J. Tager, M.D. – Medical Advisor, brings marketing expertise to Senté. He has been in the aesthetics field for ten years, helping to start Reliant Technologies, Inc., where he became VP of Marketing and introduced the Fraxel™ laser and the science of fractional photothermolysis to physicians and consumers. He has served as Chief Marketing Officer for Syneron (Nasdaq: “ELOS”).
To explore career opportunities with Senté, please visit our
careers page by clicking here.